News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 10, 2014, 10:00 ET

To Mark Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Announces Discovery Channel Documentary on Idiopathic Pulmonary Fibrosis

 In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts:...

Sep 10, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

The European Commission (EC) granted marketing authorisation for Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim's insulin glargine...

Sep 09, 2014, 08:30 ET

New Analysis of Phase III Trials Examines the Impact of Boehringer Ingelheim's IPF Therapy Nintedanib on Lung Function Decline Based on Patients' Baseline Severity

A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS™ trials, presented today at the...

Sep 08, 2014, 13:25 ET

Boehringer Ingelheim Presents Pivotal Phase III Data for the Investigational Fixed-Dose Combination of Tiotropium + Olodaterol in COPD

Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO™ 1&2 studies (NCT01431274/NCT01431287) for the...

Sep 08, 2014, 11:48 ET

New Phase III Study Shows Investigational Tiotropium Improves Lung Function in Adolescent Patients with Symptomatic Asthma

 Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in...

Sep 02, 2014, 08:18 ET

ESC Hot Line: Data Reports NVAF Patients Taking Pradaxa® (dabigatran etexilate mesylate) Experienced Slower Decline in Kidney Function Compared to Those on Warfarin

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial...

Aug 26, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

 Jardiance® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite...

Aug 25, 2014, 08:00 ET

Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at European Society of Cardiology Congress 2014

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from nine company-sponsored Pradaxa® (dabigatran etexilate mesylate)...

Aug 19, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...

Aug 18, 2014, 17:32 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

 The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is...

Aug 14, 2014, 16:35 ET

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory...

Aug 04, 2014, 09:14 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

  The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data...

Aug 01, 2014, 23:26 ET
Jardiance (R)  (empagliflozin) 10 mg tablets* *The above image does not reflect the actual size of the tablet (PRNewsFoto/Eli Lilly and Company)

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA)...

Aug 01, 2014, 08:05 ET

FDA Approves Boehringer Ingelheim's Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi® Respimat® (olodaterol)...

Jul 23, 2014, 14:00 ET

Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed

 Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ)...

Jul 16, 2014, 11:58 ET

Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy...

Jul 08, 2014, 07:38 ET

Boehringer Ingelheim's volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood

 Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in...

Jul 02, 2014, 09:00 ET

U.S. FDA Accepts NDA Filing for Boehringer Ingelheim's Investigational Nintedanib and Grants Priority Review Designation for the Treatment of Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

 The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound...